Area of research
Infectious Diseases · Public Health, Environmental and Occupational Health
Research interest
Research interests include SARS-CoV-2 and COVID-19 Research, Viral Infections and Outbreaks Research, Mosquito-borne diseases and control, and Viral Infections and Vectors.
Profile: The Kenya Multi-Site Serosurveillance (KEMIS) collaboration
Safety, tolerability, and immunogenicity of the ChAdOx1 RVF vaccine against Rift Valley fever among healthy adults in Uganda: a single-centre, single-blind, randomised, placebo-controlled, dose-escalation, phase 1 trial
Evaluation of population immunity against SARS-CoV-2 variants, EG.5.1, FY.4, BA.2.86, JN.1, JN.1.4, and KP.3.1.1 using samples from two health demographic surveillance systems in Kenya
Severe morbidity and hospital-based mortality from Rift Valley fever disease between November 2017 and March 2020 among humans in Uganda
Profile: The Kenya Multi-Site Serosurveillance (KEMIS) collaboration
SARS‐CoV‐2 seroprevalence and implications for population immunity: Evidence from two Health and Demographic Surveillance System sites in Kenya, February–December 2022
Symptom prevalence and secondary attack rate of SARS‐CoV‐2 in rural Kenyan households: A prospective cohort study
Symptom prevalence and Secondary Attack Rate of SARS-CoV-2 in Rural Kenyan Households: a prospective cohort study
Clinical manifestations of Rift Valley fever in humans: Systematic review and meta-analysis
Epidemiological impact and cost-effectiveness analysis of COVID-19 vaccination in Kenya
SARS-CoV-2 seroprevalence in three Kenyan health and demographic surveillance sites, December 2020-May 2021
Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in three Kenyan referral hospitals: Repeated cross-sectional surveys 2020–21
Serum immunoglobulin G and mucosal immunoglobulin A antibodies from prepandemic samples collected in Kilifi, Kenya, neutralize SARS-CoV-2 in vitro
Revealing the extent of the first wave of the COVID-19 pandemic in Kenya based on serological and PCR-test data
COVID-19 transmission dynamics underlying epidemic waves in Kenya
Temporal trends of SARS-CoV-2 seroprevalence during the first wave of the COVID-19 epidemic in Kenya
Seroprevalence of Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 Among Healthcare Workers in Kenya
Quantifying previous SARS-CoV-2 infection through mixture modelling of antibody levels
Comparative performance of WANTAI ELISA for total immunoglobulin to receptor binding protein and an ELISA for IgG to spike protein in detecting SARS-CoV-2 antibodies in Kenyan populations
Revealing the extent of the first wave of the COVID-19 pandemic in Kenya based on serological and PCR-test data
Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Immunoglobulin G Antibody Seroprevalence Among Truck Drivers and Assistants in Kenya
Seroprevalence of anti–SARS-CoV-2 IgG antibodies in Kenyan blood donors
Naturally Acquired Rift Valley Fever Virus Neutralizing Antibodies Predominantly Target the Gn Glycoprotein
Congenital microcephaly unrelated to flavivirus exposure in coastal Kenya
A Protective Monoclonal Antibody Targets a Site of Vulnerability on the Surface of Rift Valley Fever Virus